| (USD) | Jun 2024 | Q/Q |
|---|---|---|
| Revenue | 513K | -55% |
| Operating Income | -71.9MM | +7% |
| Operating Expenses | 72.4MM | +6% |
| Net Income | -67.6MM | +9% |
| R&D | 54.2MM | +11% |
| G&A | 18.2MM | -6% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Editas (EDIT) reports lower-than-expected second-quarter 2024 results as both earnings and revenues miss estimates. The stock falls 12.2%.
Q2 2024 Editas Medicine Inc Earnings Call
Editas (EDIT) delivered earnings and revenue surprises of -18.84% and 92.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass. AP) — Editas Medicine Inc. EDIT) on Wednesday reported a loss of $67.6 million in its second quarter.
On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end Strong financial position with runway into 2026 CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the second quarter 2024 and provided business updates. “We made significant progress in all three p
CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. ET to discuss results for the second quarter 2024 and to provide a corporate update. To access the conference call: U.S. callers should dial +1-800-343-4849 and international callers should dial +1-203-518-9848 approximately five minutes before the call begins.Par
Gene-editing stocks are a promising investment because the field is steadily advancing in the areas of medicine and biotechnology. Examples include CRISPR and other gene-editing technologies. These are becoming more precise and less time consuming, thus improving the effectiveness of the treatments and minimizing side effects. These are beneficial for the advancement of new generation therapies that can help cure genetic disorders. Lately, U.S. FDA approval of gene-editing treatments has validat
CRISPR technology, or Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that allows scientists to make precise modifications to the DNA of living organisms. It’s one of the hottest trends in the stock market today, so I’ve made a list of three of the most profitable CRISPR stocks to consider. The CRISPR technology market is rapidly evolving, with significant advancements that hold immense potential for the future of medicine. As the technology become
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. With the technology, we can fix faulty genes, or replace them with healthier genes in an attempt to cure diseases or help the body fight disease. It holds massive promise for treating cancer, cystic fibrosis, diabetes, hemophilia and AIDS. Better, the U.S. FDA has already approved gene therapy treatments for forms of cancer, muscular atrophy, hemophilia and sickle cell anemia. B